As pre-announced, Avacta has presented the results of the 3-weekly P1 Arm 1 study of its AVA6000 lead clinical asset, based on the pre|CISION™ drug development platform at the American Association for Cancer Research's annual general meeting. The update does not cover progress on the ongoing 2-weekly dosing study which is underway, and Avacta confirmed current guidance on timing including being on track to begin the dose expansion study in 2H24. There are compelling updates on the progress reported last December, which continue to confirm that AVA6000 has a very favourable safety profile and is well tolerated by patients with encouraging signs of efficacy in multiple patients with tumours expressing high levels of Fibroblast Activation Protein Alpha (FAPα) which is what cleaves AVA6000, releasing doxorubicin as the active warhead in the tumour micro environment.
